A two stage randomized, open label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered dose inhalers] adminstered either as fixed or as an adjustable regimen versus a fixed regimen of advair [salmeterol/fluticasone propionate] in subjects 12 yrs of age and older with asthma.

Trial Profile

A two stage randomized, open label, parallel group, phase III, multicenter, 7 month study to assess the efficacy and safety of Symbicort [budesonide/formoterol] pMDI [pressurised metered dose inhalers] adminstered either as fixed or as an adjustable regimen versus a fixed regimen of advair [salmeterol/fluticasone propionate] in subjects 12 yrs of age and older with asthma.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jan 2010

At a glance

  • Drugs Budesonide/formoterol; Salmeterol/fluticasone propionate
  • Indications Asthma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 May 2009 Results reported at the 105th International Conference of the American Thoracic Society.
    • 17 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top